Reuben S Harris

List of Publications by Year
in descending order

205 papers	18,928 citations	13865 67 h-index	14208 128 g-index
226 all docs	226 docs citations	226 times ranked	11070 citing authors

#	Article	IF	Citations
1	DNA Deamination Mediates Innate Immunity to Retroviral Infection. Cell, 2003, 113, 803-809.	28.9	1,247
2	AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature, 2002, 418, 99-104.	27.8	808
3	APOBEC3B is an enzymatic source of mutation in breast cancer. Nature, 2013, 494, 366-370.	27.8	758
4	Evidence for APOBEC3B mutagenesis in multiple human cancers. Nature Genetics, 2013, 45, 977-983.	21.4	660
5	Retroviral restriction by APOBEC proteins. Nature Reviews Immunology, 2004, 4, 868-877.	22.7	581
6	RNA Editing Enzyme APOBEC1 and Some of Its Homologs Can Act as DNA Mutators. Molecular Cell, 2002, 10, 1247-1253.	9.7	525
7	APOBECs and virus restriction. Virology, 2015, 479-480, 131-145.	2.4	439
8	The Vif Protein of HIV Triggers Degradation of the Human Antiretroviral DNA Deaminase APOBEC3G. Current Biology, 2003, 13, 2009-2013.	3.9	427
9	APOBEC3F Properties and Hypermutation Preferences Indicate Activity against HIV-1 In Vivo. Current Biology, 2004, 14, 1385-1391.	3.9	411
10	APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. Cancer Discovery, 2015, 5, 704-712.	9.4	392
11	Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Research, 2010, 38, 4274-4284.	14.5	323
12	Vif hijacks CBF-Î² to degrade APOBEC3G and promote HIV-1 infection. Nature, 2012, 481, 371-375.	27.8	312
13	Human and Rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H Demonstrate a Conserved Capacity To Restrict Vif-Deficient HIV-1. Journal of Virology, 2011, 85, 11220-11234.	3.4	310
14	Comparison of the Differential Context-dependence of DNA Deamination by APOBEC Enzymes: Correlation with Mutation Spectra in Vivo. Journal of Molecular Biology, 2004, 337, 585-596.	4.2	306
15	APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nature Structural and Molecular Biology, 2010, 17, 222-229.	8.2	295
16	Human Immunodeficiency Virus Type 1 cDNAs Produced in the Presence of APOBEC3G Exhibit Defects in Plus-Strand DNA Transfer and Integration. Journal of Virology, 2007, 81, 7099-7110.	3.4	247
17	The Restriction Factors of Human Immunodeficiency Virus. Journal of Biological Chemistry, 2012, 287, 40875-40883.	3.4	244
18	APOBEC3B and APOBEC3F Inhibit L1 Retrotransposition by a DNA Deamination-independent Mechanism*. Journal of Biological Chemistry, 2006, 281, 16837-16841.	3.4	243

#	Article	IF	Citations
19	Extensive somatic L1 retrotransposition in colorectal tumors. Genome Research, 2012, 22, 2328-2338.	5.5	235
20	Guidelines for Naming Nonprimate APOBEC3 Genes and Proteins. Journal of Virology, 2009, 83, 494-497.	3.4	217
21	Immunity through DNA deamination. Trends in Biochemical Sciences, 2003, 28, 305-312.	7.5	214
22	Structural basis for targeted DNA cytosine deamination and mutagenesis by APOBEC3A and APOBEC3B. Nature Structural and Molecular Biology, 2017, 24, 131-139.	8.2	214
23	AID Is Essential for Immunoglobulin V Gene Conversion in a Cultured B Cell Line. Current Biology, 2002, 12, 435-438.	3.9	205
24	Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature, 2008, 452, 116-119.	27.8	202
25	The APOBEC3 Family of Retroelement Restriction Factors. Current Topics in Microbiology and Immunology, 2013, 371, 1-27.	1.1	177
26	The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Science Advances, 2016, 2, e1601737.	10.3	175
27	Increasing Cas9-mediated homology-directed repair efficiency through covalent tethering of DNA repair template. Communications Biology, 2018, 1, 54.	4.4	175
28	Human Papillomavirus E6 Triggers Upregulation of the Antiviral and Cancer Genomic DNA Deaminase APOBEC3B. MBio, 2014, 5, .	4.1	172
29	Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Reviews in Molecular Medicine, 2010, 12, e4.	3.9	171
30	The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Molecular Biology, 2008, 9, 104.	3.0	169
31	The Retroviral Hypermutation Specificity of APOBEC3F and APOBEC3G Is Governed by the C-terminal DNA Cytosine Deaminase Domain. Journal of Biological Chemistry, 2005, 280, 10920-10924.	3.4	166
32	APOBEC3G Contributes to HIV-1 Variation through Sublethal Mutagenesis. Journal of Virology, 2010, 84, 7396-7404.	3.4	161
33	APOBEC3B Upregulation and Genomic Mutation Patterns in Serous Ovarian Carcinoma. Cancer Research, 2013, 73, 7222-7231.	0.9	153
34	The DNA Deaminase Activity of Human APOBEC3G Is Required for Ty1, MusD, and Human Immunodeficiency Virus Type 1 Restriction. Journal of Virology, 2008, 82, 2652-2660.	3.4	149
35	Opposing Roles of the Holliday Junction Processing Systems of Escherichia coli in Recombination-Dependent Adaptive Mutation. Genetics, 1996, 142, 681-691.	2.9	147
36	The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to breast and lung cancer mutagenesis. Nature Communications, 2016, 7, 12918.	12.8	146

#	Article	IF	Citations
37	Role for Msh5 in the regulation of Ig class switch recombination. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 7193-7198.	7.1	142
38	Elevated APOBEC3B Correlates with Poor Outcomes for Estrogen-Receptor-Positive Breast Cancers. Hormones and Cancer, 2014, 5, 405-413.	4.9	140
39	DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer. Genome Biology, 2016, 17, 185.	8.8	140
40	APOBEC Enzymes as Targets for Virus and Cancer Therapy. Cell Chemical Biology, 2018, 25, 36-49.	5.2	137
41	APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9854-9859.	7.1	136
42	Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. Annals of Oncology, 2018, 29, 563-572.	1.2	135
43	Subcellular localization of the APOBEC3 proteins during mitosis and implications for genomic DNA deamination. Cell Cycle, 2013, 12, 762-772.	2.6	127
44	Methylcytosine and Normal Cytosine Deamination by the Foreign DNA Restriction Enzyme APOBEC3A. Journal of Biological Chemistry, 2012, 287, 34801-34808.	3.4	120
45	Crystal Structure of the APOBEC3G Catalytic Domain Reveals Potential Oligomerization Interfaces. Structure, 2010, 18, 28-38.	3.3	116
46	The PKC/NF-Î²B Signaling Pathway Induces APOBEC3B Expression in Multiple Human Cancers. Cancer Research, 2015, 75, 4538-4547.	0.9	116
47	First-In-Class Small Molecule Inhibitors of the Single-Strand DNA Cytosine Deaminase APOBEC3G. ACS Chemical Biology, 2012, 7, 506-517.	3.4	112
48	Transient and Heritable Mutators in Adaptive Evolution in the Lab and in Nature. Genetics, 1998, 148, 1559-1566.	2.9	112
49	Engineered proteins detect spontaneous DNA breakage in human and bacterial cells. ELife, 2013, 2, e01222.	6.0	105
50	An Extended Structure of the APOBEC3G Catalytic Domain Suggests a Unique Holoenzyme Model. Journal of Molecular Biology, 2009, 389, 819-832.	4.2	101
51	Merkel Cell Polyomavirus Exhibits Dominant Control of the Tumor Genome and Transcriptome in Virus-Associated Merkel Cell Carcinoma. MBio, 2017, 8, .	4.1	100
52	Molecular handles on adaptive mutation. Molecular Microbiology, 1995, 18, 185-189.	2.5	95
53	Epsteinâ€“Barr virus BORF2 inhibits cellular APOBEC3B to preserve viral genome integrity. Nature Microbiology, 2019, 4, 78-88.	13.3	95
54	Natural Polymorphisms in Human APOBEC3H and HIV-1 Vif Combine in Primary T Lymphocytes to Affect Viral G-to-A Mutation Levels and Infectivity. PLoS Genetics, 2014, 10, e1004761.	3.5	92

#	Article	IF	Citations
55	Atomic Force Microscopy Studies Provide Direct Evidence for Dimerization of the HIV Restriction Factor APOBEC3G. Journal of Biological Chemistry, 2011, 286, 3387-3395.	3.4	91
56	Endogenous Origins of HIV-1 G-to-A Hypermutation and Restriction in the Nonpermissive T Cell Line CEM2n. PLoS Pathogens, 2012, 8, e1002800.	4.7	90
57	Crystal Structure of the DNA Deaminase APOBEC3B Catalytic Domain. Journal of Biological Chemistry, 2015, 290, 28120-28130.	3.4	89
58	APOBEC3A catalyzes mutation and drives carcinogenesis in vivo. Journal of Experimental Medicine, 2020, 217, .	8.5	87
59	Lentiviral Vif Degrades the APOBEC3Z3/APOBEC3H Protein of Its Mammalian Host and Is Capable of Cross-Species Activity. Journal of Virology, 2010, 84, 8193-8201.	3.4	86
60	Crystal Structure of the DNA Cytosine Deaminase APOBEC3F: The Catalytically Active and HIV-1 Vif-Binding Domain. Structure, 2013, 21, 1042-1050.	3.3	85
61	Structure of the Vif-binding domain of the antiviral enzyme APOBEC3G. Nature Structural and Molecular Biology, 2015, 22, 485-491.	8.2	84
62	Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. British Journal of Cancer, 2017, 117, 113-123.	6.4	84
63	Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer. Breast Cancer Research, 2015, 17, 8.	5.0	82
64	The Local Dinucleotide Preference of APOBEC3G Can Be Altered from 5â€²-CC to 5â€²-TC by a Single Amino Acid Substitution. Journal of Molecular Biology, 2013, 425, 4442-4454.	4.2	80
65	Functional Upregulation of the DNA Cytosine Deaminase APOBEC3B by Polyomaviruses. Journal of Virology, 2016, 90, 6379-6386.	3.4	80
66	APOBEC3B and AID Have Similar Nuclear Import Mechanisms. Journal of Molecular Biology, 2012, 419, 301-314.	4.2	79
67	DNA deamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses. Nature Immunology, 2003, 4, 641-643.	14.5	77
68	Evolution of HIV-1 Isolates that Use a Novel Vif-Independent Mechanism to Resist Restriction by Human APOBEC3G. Current Biology, 2008, 18, 819-824.	3.9	75
69	Induction of APOBEC3 Exacerbates DNA Replication Stress and Chromosomal Instability in Early Breast and Lung Cancer Evolution. Cancer Discovery, 2021, 11, 2456-2473.	9.4	74
70	Endogenous APOBEC3A DNA Cytosine Deaminase Is Cytoplasmic and Nongenotoxic. Journal of Biological Chemistry, 2013, 288, 17253-17260.	3.4	73
71	Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins. Nucleic Acids Research, 2006, 34, 5683-5694.	14.5	71
72	Somatic hypermutation and the three R's: repair, replication and recombination. Mutation Research - Reviews in Mutation Research, 1999, 436, 157-178.	5.5	70

#	Article	IF	Citations
73	Two Regions within the Amino-Terminal Half of APOBEC3G Cooperate To Determine Cytoplasmic Localization. Journal of Virology, 2008, 82, 9591-9599.	3.4	68
74	APOBEC3 Multimerization Correlates with HIV-1 Packaging and Restriction Activity in Living Cells. Journal of Molecular Biology, 2014, 426, 1296-1307.	4.2	68
75	Vif Proteins of Human and Simian Immunodeficiency Viruses Require Cellular CBFÎ² To Degrade APOBEC3 Restriction Factors. Journal of Virology, 2012, 86, 2874-2877.	3.4	65
76	The Antiviral and Cancer Genomic DNA Deaminase APOBEC3H Is Regulated by an RNA-Mediated Dimerization Mechanism. Molecular Cell, 2018, 69, 75-86.e9.	9.7	65
77	AID can restrict L1 retrotransposition suggesting a dual role in innate and adaptive immunity. Nucleic Acids Research, 2009, 37, 1854-1867.	14.5	64
78	APOBEC3G enhances lymphoma cell radioresistance by promoting cytidine deaminase-dependent DNA repair. Blood, 2012, 120, 366-375.	1.4	63
79	Characterization of BK Polyomaviruses from Kidney Transplant Recipients Suggests a Role for APOBEC3 in Driving In-Host Virus Evolution. Cell Host and Microbe, 2018, 23, 628-635.e7.	11.0	63
80	Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA. Nature, 2022, 602, 510-517.	27.8	60
81	APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma. Clinical Cancer Research, 2016, 22, 4746-4755.	7.0	59
82	Differential Evolution of Antiretroviral Restriction Factors in Pteropid Bats as Revealed by APOBEC3 Gene Complexity. Molecular Biology and Evolution, 2018, 35, 1626-1637.	8.9	59
83	A fluorescent reporter for quantification and enrichment of DNA editing by APOBECâ€“Cas9 or cleavage by Cas9 in living cells. Nucleic Acids Research, 2018, 46, e84-e84.	14.5	56
84	Inhibition of a NEDD8 Cascade Restores Restriction of HIV by APOBEC3G. PLoS Pathogens, 2012, 8, e1003085.	4.7	55
85	APOBEC3B: Pathological consequences of an innate immune DNA mutator. Biomedical Journal, 2015, 38, 102.	3.1	54
86	A direct role for DNA polymerase III in adaptive reversion of a frameshift mutation in Escherichia coli. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1997, 375, 19-24.	1.0	51
87	Impact of H216 on the DNA Binding and Catalytic Activities of the HIV Restriction Factor APOBEC3G. Journal of Virology, 2013, 87, 7008-7014.	3.4	49
88	Extensive mutagenesis experiments corroborate a structural model for the DNA deaminase domain of APOBEC3G. FEBS Letters, 2007, 581, 4761-4766.	2.8	48
89	Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance. AIDS Reviews, 2006, 8, 148-57.	1.0	48
90	APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. Nature Communications, 2020, 11, 790.	12.8	47

#	Article	IF	Citations
91	Enhancing immunity to HIV through APOBEC. Nature Biotechnology, 2008, 26, 1089-1090.	17.5	46
92	A Single Amino Acid in Human APOBEC3F Alters Susceptibility to HIV-1 Vif. Journal of Biological Chemistry, 2010, 285, 40785-40792.	3.4	46
93	Nanoscale Structure and Dynamics of ABOBEC3G Complexes with Single-Stranded DNA. Biochemistry, 2012, 51, 6432-6440.	2.5	46
94	Competition of Escherichia coli DNA Polymerases I, II and III with DNA Pol IV in Stressed Cells. PLoS ONE, 2010, 5, e10862.	2.5	45
95	Long-Term Restriction by APOBEC3F Selects Human Immunodeficiency Virus Type 1 Variants with Restored Vif Function. Journal of Virology, 2010, 84, 10209-10219.	3.4	45
96	Mutation Signatures Including APOBEC in Cancer Cell Lines. JNCI Cancer Spectrum, 2018, 2, .	2.9	45
97	The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer. Clinical Cancer Research, 2020, 26, 3397-3407.	7.0	45
98	Unique DNA Repair Gene Variations and Potential Associations with the Primary Antibody Deficiency Syndromes IgAD and CVID. PLoS ONE, 2010, 5, e12260.	2.5	45
99	Cancer mutation signatures, DNA damage mechanisms, and potential clinical implications. Genome Medicine, 2013, 5, 87.	8.2	44
100	Small molecules that inhibit Vif-induced degradation of APOBEC3G. Virology Journal, 2014, 11, 122.	3.4	44
101	Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma. Clinical Cancer Research, 2019, 25, 674-686.	7.0	44
102	APOBECs and Herpesviruses. Viruses, 2021, 13, 390.	3.3	44
103	The Restriction of Zoonotic PERV Transmission by Human APOBEC3G. PLoS ONE, 2007, 2, e893.	2.5	44
104	Lineage-Specific Viral Hijacking of Non-canonical E3ÂUbiquitin Ligase Cofactors in the Evolution of Vif Anti-APOBEC3 Activity. Cell Reports, 2015, 11, 1236-1250.	6.4	42
105	Transcriptional regulation of APOBEC3 antiviral immunity through the CBF-Î²/RUNX axis. Science Advances, 2015, 1, e1500296.	10.3	42
106	APOBEC3B Nuclear Localization Requires Two Distinct N-Terminal Domain Surfaces. Journal of Molecular Biology, 2018, 430, 2695-2708.	4.2	42
107	MDM2 can interact with the C-terminus of AID but it is inessential for antibody diversification in DT40 B cells. Molecular Immunology, 2006, 43, 1099-1108.	2.2	41
108	Human Immunodeficiency Virus Type 1 Vif Induces Cell Cycle Delay via Recruitment of the Same E3 Ubiquitin Ligase Complex That Targets APOBEC3 Proteins for Degradation. Journal of Virology, 2008, 82, 9265-9272.	3.4	41

#	Article	IF	Citations
109	HIV-1 competition experiments in humanized mice show that APOBEC3H imposes selective pressure and promotes virus adaptation. PLoS Pathogens, 2017, 13, e1006348.	4.7	41
110	Recombination-dependent mutation in non-dividing cells. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1996, 350, 69-76.	1.0	39
111	Atomic force microscopy studies of APOBEC3G oligomerization and dynamics. Journal of Structural Biology, 2013, 184, 217-225.	2.8	38
112	A panel of eGFP reporters for single base editing by APOBEC-Cas9 editosome complexes. Scientific Reports, 2019, 9, 497.	3.3	38
113	The SAMHD1 dNTP Triphosphohydrolase Is Controlled by a Redox Switch. Antioxidants and Redox Signaling, 2017, 27, 1317-1331.	5.4	37
114	HIV-1 adaptation studies reveal a novel Env-mediated homeostasis mechanism for evading lethal hypermutation by APOBEC3G. PLoS Pathogens, 2018, 14, e1007010.	4.7	35
115	Polyomavirus T Antigen InducesAPOBEC3BExpression Using an LXCXE-Dependent and TP53-Independent Mechanism. MBio, 2019, 10, .	4.1	35
116	APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis. Nature Cancer, 2021, 2, 1338-1356.	13.2	35
117	Phosphorylation Directly Regulates the Intrinsic DNA Cytidine Deaminase Activity of Activation-induced Deaminase and APOBEC3G Protein. Journal of Biological Chemistry, 2011, 286, 26568-26575.	3.4	34
118	The Binding Interface between Human APOBEC3F and HIV-1 Vif Elucidated by Genetic and Computational Approaches. Cell Reports, 2015, 13, 1781-1788.	6.4	34
119	The deaminase APOBEC3B triggers the death of cells lacking uracil DNA glycosylase. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22158-22163.	7.1	34
120	Smallâ€Molecule APOBEC3G DNA Cytosine Deaminase Inhibitors Based on a 4â€Aminoâ€1,2,4â€triazoleâ€3â€thiol Scaffold. ChemMedChem, 2013, 8, 112-117.	3.2	33
121	Mismatch Repair in Escherichia coli Cells Lacking Single-Strand Exonucleases ExoI, ExoVII, and RecJ. Journal of Bacteriology, 1998, 180, 989-993.	2.2	33
122	Mutation Processes in 293-Based Clones Overexpressing the DNA Cytosine Deaminase APOBEC3B. PLoS ONE, 2016, 11, e0155391.	2.5	33
123	1.92 Angstrom Zinc-Free APOBEC3F Catalytic Domain Crystal Structure. Journal of Molecular Biology, 2016, 428, 2307-2316.	4.2	32
124	Computational Model and Dynamics of Monomeric Full-Length APOBEC3G. ACS Central Science, 2017, 3, 1180-1188.	11.3	32
125	Cellular Requirements for Bovine Immunodeficiency Virus Vif-Mediated Inactivation of Bovine APOBEC3 Proteins. Journal of Virology, 2014, 88, 12528-12540.	3.4	31
126	A Conserved Mechanism of APOBEC3 Relocalization by Herpesviral Ribonucleotide Reductase Large Subunits. Journal of Virology, 2019, 93, .	3.4	31

#	Article	IF	Citations
127	Epstein-Barr Virus and the Somatic Hypermutation of Immunoglobulin Genes in Burkitt's Lymphoma Cells. Journal of Virology, 2001, 75, 10488-10492.	3.4	30
128	HIV Type 1 Viral Infectivity Factor and the RUNX Transcription Factors Interact with Core Binding Factor Î² on Genetically Distinct Surfaces. AIDS Research and Human Retroviruses, 2012, 28, 1543-1551.	1.1	30
129	A Rabbit Monoclonal Antibody against the Antiviral and Cancer Genomic DNA Mutating Enzyme APOBEC3B. Antibodies, 2019, 8, 47.	2.5	30
130	Inhibiting APOBEC3 Activity with Single-Stranded DNA Containing 2â€²-Deoxyzebularine Analogues. Biochemistry, 2019, 58, 391-400.	2.5	29
131	Structural basis of host protein hijacking in human T-cell leukemia virus integration. Nature Communications, 2020, 11, 3121.	12.8	29
132	Conformational Switch Regulates the DNA Cytosine Deaminase Activity of Human APOBEC3B. Scientific Reports, 2017, 7, 17415.	3.3	28
133	Genetic and mechanistic basis for APOBEC3H alternative splicing, retrovirus restriction, and counteraction by HIV-1 protease. Nature Communications, 2018, 9, 4137.	12.8	28
134	HIV-1 Vif Triggers Cell Cycle Arrest by Degrading Cellular PPP2R5 Phospho-regulators. Cell Reports, 2019, 29, 1057-1065.e4.	6.4	28
135	Optimal Translation Initiation Enables Vif-Deficient Human Immunodeficiency Virus Type 1 To Escape Restriction by APOBEC3G. Journal of Virology, 2009, 83, 5956-5960.	3.4	27
136	Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS. Future Virology, 2009, 4, 605-619.	1.8	26
137	Directed DNA deamination by AID/APOBEC3 in immunity. Current Biology, 2006, 16, R186-R189.	3.9	25
138	Natural APOBEC3C variants can elicit differential HIV-1 restriction activity. Retrovirology, 2018, 15, 78.	2.0	25
139	Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B. ELife, 2020, 9, .	6.0	25
140	Dispersed Sites of HIV Vif-Dependent Polyubiquitination in the DNA Deaminase APOBEC3F. Journal of Molecular Biology, 2013, 425, 1172-1182.	4.2	22
141	Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus. Virology, 2014, 450-451, 49-54.	2.4	22
142	Oxidative Reactivities of 2-Furylquinolines: Ubiquitous Scaffolds in Common High-Throughput Screening Libraries. Journal of Medicinal Chemistry, 2015, 58, 7419-7430.	6.4	22
143	Endogenous APOBEC3B overexpression characterizes HPV-positive and HPV-negative oral epithelial dysplasias and head and neck cancers. Modern Pathology, 2021, 34, 280-290.	5.5	22
144	Evolutionary Paradigms from Ancient and Ongoing Conflicts between the Lentiviral Vif Protein and Mammalian APOBEC3 Enzymes. PLoS Pathogens, 2016, 12, e1005958.	4.7	22

#	Article	IF	Citations
145	Recombination-based mechanisms for somatic hypermutation. Immunological Reviews, 1998, 162, 67-76.	6.0	21
146	Interaction of APOBEC3A with DNA Assessed by Atomic Force Microscopy. PLoS ONE, 2014, 9, e99354.	2.5	21
147	The DNA deaminase APOBEC3B interacts with the cell-cycle protein CDK4 and disrupts CDK4-mediated nuclear import of Cyclin D1. Journal of Biological Chemistry, 2019, 294, 12099-12111.	3.4	21
148	Induction of APOBEC3-mediated genomic damage in urothelium implicates BK polyomavirus (BKPyV) as a hit-and-run driver for bladder cancer. Oncogene, 2022, 41, 2139-2151.	5.9	21
149	Defining HIV-1 Vif residues that interact with CBFÎ² by site-directed mutagenesis. Virology, 2014, 449, 82-87.	2.4	19
150	The Multidimensional Nature of Antiviral Innate Immunity. Cell Host and Microbe, 2015, 17, 423-425.	11.0	19
151	HIV-1 restriction by endogenous APOBEC3G in the myeloid cell line THP-1. Journal of General Virology, 2019, 100, 1140-1152.	2.9	19
152	Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M ^{pro} /3CL ^{pro} in Living Cells. MBio, 2022, 13, e0078422.	4.1	19
153	APOBEC3G Interacts with ssDNA by Two Modes: AFM Studies. Scientific Reports, 2015, 5, 15648.	3.3	18
154	A lentivirus-based system for Cas9/gRNA expression and subsequent removal by Cre-mediated recombination. Methods, 2019, 156, 79-84.	3.8	17
155	Degradation of the cancer genomic DNA deaminase APOBEC3B by SIV Vif. Oncotarget, 2015, 6, 39969-39979.	1.8	17
156	A Comparison of Two Single-Stranded DNA Binding Models by Mutational Analysis of APOBEC3G. Biology, 2012, 1, 260-276.	2.8	16
157	Vif determines the requirement for CBF-Î² in APOBEC3 degradation. Journal of General Virology, 2015, 96, 887-892.	2.9	16
158	A Naturally Occurring Domestic Cat APOBEC3 Variant Confers Resistance to Feline Immunodeficiency Virus Infection. Journal of Virology, 2016, 90, 474-485.	3.4	16
159	APOBEC3H Subcellular Localization Determinants Define Zipcode for Targeting HIV-1 for Restriction. Molecular and Cellular Biology, 2018, 38, .	2.3	16
160	A role for gorilla APOBEC3G in shaping lentivirus evolution including transmission to humans. PLoS Pathogens, 2020, 16, e1008812.	4.7	16
161	Dual Functionality of HIV-1 Vif in APOBEC3 Counteraction and Cell Cycle Arrest. Frontiers in Microbiology, 2020, 11, 622012.	3.5	16
162	DNA-Dependent Protein Kinase Inhibits AID-Induced Antibody Gene Conversion. PLoS Biology, 2007, 5, e80.	5.6	15

#	Article	IF	Citations
163	Cryo-EM structure of the EBV ribonucleotide reductase BORF2 and mechanism of APOBEC3B inhibition. Science Advances, 2022, 8, eabm2827.	10.3	15
164	APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. Molecular Therapy - Oncolytics, 2018, 11, 1-13.	4.4	14
165	APOBEC3F Determinants of HIV-1 Vif Sensitivity. Journal of Virology, 2014, 88, 12923-12927.	3.4	13
166	Nanoscale Characterization of Interaction of APOBEC3G with RNA. Biochemistry, 2017, 56, 1473-1481.	2.5	13
167	Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment. Cancer Immunology Research, 2019, 7, 828-840.	3.4	13
168	APOBEC3 inhibits DEAD-END function to regulate microRNA activity. BMC Molecular Biology, 2013, 14, 16.	3.0	12
169	Opossum APOBEC1 is a DNA mutator with retrovirus and retroelement restriction activity. Scientific Reports, 2017, 7, 46719.	3.3	12
170	The current toolbox for APOBEC drug discovery. Trends in Pharmacological Sciences, 2022, 43, 362-377.	8.7	12
171	Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G. Journal of Virology, 2018, 92, .	3.4	10
172	Determinants of Oligonucleotide Selectivity of APOBEC3B. Journal of Chemical Information and Modeling, 2019, 59, 2264-2273.	5.4	10
173	Structural basis for recognition of distinct deaminated DNA lesions by endonuclease Q. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	10
174	The Interaction between AID and CIB1 Is Nonessential for Antibody Gene Diversification by Gene Conversion or Class Switch Recombination. PLoS ONE, 2010, 5, e11660.	2.5	9
175	Active site plasticity and possible modes of chemical inhibition of the human DNA deaminase APOBEC3B. FASEB BioAdvances, 2020, 2, 49-58.	2.4	9
176	R-Spondins 2 and 3 Are Overexpressed in a Subset of Human Colon and Breast Cancers. DNA and Cell Biology, 2021, 40, 70-79.	1.9	9
177	A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition. Communications Biology, 2022, 5, 391.	4.4	9
178	Single-Molecule Force Spectroscopy Studies of APOBEC3Aâ€“Single-Stranded DNA Complexes. Biochemistry, 2016, 55, 3102-3106.	2.5	8
179	D316 is critical for the enzymatic activity and HIV-1 restriction potential of human and rhesus APOBEC3B. Virology, 2013, 441, 31-39.	2.4	7
180	Reassessing APOBEC3G Inhibition by HIV-1 Vif-Derived Peptides. Journal of Molecular Biology, 2017, 429, 88-96.	4.2	7

#	Article	IF	Citations
181	MagnEditâ€"interacting factors that recruit DNA-editing enzymes to single base targets. Life Science Alliance, 2020, 3, e201900606.	2.8	7
182	Functional and Structural Insights into a Vif/PPP2R5 Complex Elucidated Using Patient HIV-1 Isolates and Computational Modeling. Journal of Virology, 2020, 94, .	3.4	6
183	Small-Angle X-ray Scattering Models of APOBEC3B Catalytic Domain in a Complex with a Single-Stranded DNA Inhibitor. Viruses, 2021, 13, 290.	3.3	6
184	The Role of RNA in HIV-1 Vif-Mediated Degradation of APOBEC3H. Journal of Molecular Biology, 2019, 431, 5019-5031.	4.2	5
185	Evolved Proteins Inhibit Entry of Enfuvirtide-Resistant HIV-1. ACS Infectious Diseases, 2019, 5, 634-640.	3.8	5
186	Demystifying Cell Cycle Arrest by HIV-1 Vif. Trends in Microbiology, 2021, 29, 381-384.	7.7	5
187	Small Molecule Inhibitors of Activation-Induced Deaminase Decrease Class Switch Recombination in B Cells. ACS Pharmacology and Translational Science, 2021, 4, 1214-1226.	4.9	5
188	CEM-T4 Cells Do Not Lack an APOBEC3G Cofactor. PLoS Pathogens, 2009, 5, e1000528.	4.7	5
189	Dancin' deaminase. Nature Structural and Molecular Biology, 2006, 13, 380-381.	8.2	3
190	Helixâ€Grafted Pleckstrin Homology Domains Suppress HIVâ€1 Infection of CD4â€Positive Cells. ChemBioChem, 2016, 17, 1945-1950.	2.6	3
191	APOBEC3B lysine residues are dispensable for DNA cytosine deamination, HIV-1 restriction, and nuclear localization. Virology, 2017, 511, 74-81.	2.4	3
192	Evaluation of sequence variability in HIV-1 gp41 C-peptide helix-grafted proteins. Bioorganic and Medicinal Chemistry, 2018, 26, 1220-1224.	3.0	3
193	Structural Characterization of a Minimal Antibody against Human APOBEC3B. Viruses, 2021, 13, 663.	3.3	2
194	The Antiviral and Cancer Genomic DNA Deaminase APOBEC3H Is Regulated by a RNA-Mediated Dimerization Mechanism. SSRN Electronic Journal, 0, , .	0.4	1
195	Abstract PD1-06: Apobec mutagenesis is a pervasive feature of poor prognosis breast cancer associating with ESR1 wild type, endocrine resistant disease. Cancer Research, 2022, 82, PD1-06-PD1-06.	0.9	1
196	Antibody Gene Diversification by Aid-Catalyzed DNA Editing. , 0, , 31-70.		0
197	Host Factors that Restrict Retrovirus Replication. , 2009, , 297-334.		0
198	Retrovirus Restriction Factors. , 2010, , 407-437.		0

#	Article	IF	Citations
199	APOBECs and Their Role in Proviral DNA Synthesis. , 2013, , 253-280.		0
200	APOBEC3B Signature Mutations Benefit BK Polyomavirus. SSRN Electronic Journal, 0, , .	0.4	0
201	A role for gorilla APOBEC3G in shaping lentivirus evolution including transmission to humans. , 2020, 16, e1008812.		0
202	A role for gorilla APOBEC3G in shaping lentivirus evolution including transmission to humans. , 2020, 16, e1008812.		0
203	A role for gorilla APOBEC3G in shaping lentivirus evolution including transmission to humans. , 2020, 16, e1008812.		0
204	A role for gorilla APOBEC3G in shaping lentivirus evolution including transmission to humans. , 2020, 16, e1008812.		0
205	A role for gorilla APOBEC3G in shaping lentivirus evolution including transmission to humans. , 2020, 16, e1008812.		0